Cells behaving badly: A theoretical model for the Fas/FasL system in tumour immunology

Mathematical Biosciences

Volumn 179, Issue 2, 2002, Pages 113-129

  Webb, Steven D ^a,b   Sherratt, Jonathan A ^b   Fish, Reginald G ^c  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

^c VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

Apoptosis; Cancer cells; FasL; Immune evasion; Modelling

Indexed keywords

CELLS; ENZYME INHIBITION; MATHEMATICAL MODELS; TUMORS;

DEATH SIGNALS;

BIOMEDICAL ENGINEERING;

ANGIOGENESIS INHIBITOR; FAS ANTIGEN; FAS LIGAND; IMMUNOMODULATING AGENT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

CANCER; CYTOLOGY;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; DOWN REGULATION; ENZYME INACTIVATION; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; LYMPHOCYTE; MATHEMATICAL MODEL; SIGNAL TRANSDUCTION; THEORETICAL MODEL; TUMOR CELL; TUMOR IMMUNOLOGY;

ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; HUMANS; LYMPHOCYTE ACTIVATION; MATRIX METALLOPROTEINASES; MEMBRANE GLYCOPROTEINS; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0036719129     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-5564(02)00120-7     Document Type: Article

References (68)

1. Is cancer dangerous to the immune system?
2. Immunology: Improving on nature in the twenty-first century
3. Lymphocyte - Mediated cytolysis and disease
4. The host-tumour immune conflict: From immunosuppression to resistance and destruction
5. Inhibition of death receptor signals by cellular FLIP
6. The Fas counterattack: Cancer as a site of immune privilege
7. Fas and Fas-L in the homeostatic regulation of immune responses
8. A vision of cell death: Insights into immune privilege
9. Three functional forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing
10. Membrane Fas ligand kills human peripheral blood T-lymphocytes and soluble Fas ligand blocks the killing
11. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer
12. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitive RT-PCR
13. Fas ligand in human serum
14. Elevated soluble Fas (sFas) levels in non-hematopoietic human malignancy
15. Down-regulation of Fas ligand by shedding
16. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis
17. Tumours and the immune system: The effects of a tumour growth modulator
18. The dynamics of growth factor-modified immune response to cancer growth: One dimensional models
19. Modelling immunotherapy of the tumour-immune interaction
20. Pattern formation and spatiotemporal irregularity in a model for macrophage-tumour interaction
21. Effects of vascularization on lymphocyte/tumour cell dynamics: Qualitative features
22. Harpoon model for cell-cell adhesion and recognition of target cells by the natural killer cells
23. Cytokine-modulated regulation of helper T-cell populations
24. Tumours immunological escape of
25. Modelling the macrophage invasion of tumours: Effects on growth and composition
26. Fas ligand induced apoptosis as a mechanism of immune privilege
27. TCR/CD3 coupling to Fas-based cytotoxicity
28. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T-cells and natural killer cells
29. The role of Fas/Fas-L in immunosuppression induced by human tumours
30. Molecular-cloning and expression of the Fas ligand, a novel member of the tumor-necrosis-factor family
31. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen
32. Human monocytic cells contain high levels of intracellular Fas ligand: Rapid release following cellular activation
33. A perturbation problem arising from the modelling of soluble Fas ligand in tumour immunology
34. Fas-Fas ligand-based interactions between tumour cells and tumour specific cytotoxic T lymphocytes: A lethal two-way street
35. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumour-induced suppression of immune surveillance
36. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
37. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer
38. Expression of Fas (Apo-1/CD95) in tumour-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma
39. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma
40. Human pancreatic adenocarcinomas express Fas and Fas-L yet are resistant to Fas-mediated apoptosis
41. CD95 ligand: Lethal weapon against malignant glioma
42. Fas ligand is expressed in human squamous carcinomas of the head and neck and its promotes apoptosis of T lymphocytes
43. Expression of Fas (CD95/APO-1) ligand by human breast cancers: Significance for tumour immune privilege
44. Expression of Fas ligand and other apoptosis-related genes and their prognostic significant in epithelial ovarian neoplasms
45. Summary of the international cancer microenvironment from meeting held in Pittsburgh, Pennsylvania
46. Human melanoma cells do not express Fas (Apo-1/CD95) ligand
47. Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis
48. The Fas counterattack in vivo: Apoptotic depletion of Tumour-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
49. Fas ligand mediates activation-induced apoptosis cell death in human lymphocytes
50. Fas-mediated suicide of tumour-reactive T-cells following activation by specific tumour: Selective rescue by caspase inhibition
51. Metalloproteinase-mediated release of human Fas ligand
52. Fas-mediated apoptosis in Ewings Sarcoma cell lines by metalloproteinase inhibitors
53. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and non-cancerous tissues
54. Therapeutic opportunities from the pharmacological manipulation of the Fas system
55. Prognostic relevance of altered Fas (CD95)-system in human breast cancer
56. Changing views of the role of matrix metalloproteinases in metastasis
57. Matrix metalloproteinases: Biological activity and clinical applications
58. Matrilysin in early stage intestinal tumorigenesis
59. Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo
60. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems
61. Fas drives cell cycle progression in glioma cells via extra cellular signal regulated kinase activation
62. Tumour expression of Fas ligand (CD95L) and the consequences
63. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumour escape
64. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumour cell survival
65. Anti-angiogenic agents: Clinical trial design and therapies in development